Product candidate	Target indication	Development status
KRX-0401 (perifosine)	Multiple myeloma Colorectal cancer Multiple other forms of cancer	Phase 3 ongoing, under SPA Phase 3 pending, under SPA Phase 2 trials ongoing
ZerenexTM (ferric citrate)	Hyperphosphatemia in patients with end-stage renal disease	U.S. Phase 2 complete; U.S. Phase 3 program pending; Japan Phase 2 ongoing by sublicensee (JT and Torii)